Immix Biopharma is a pre-revenue, cash-burning biotech whose value rests on a single pipeline asset (NXC-201) and an analyst target far above the current $8.15 price, but weak quality and deteriorating momentum limit conviction.
Thesis pillars
- Single Asset Pipeline Concentration↑Improving
- Cash Burning No Revenue→Stable
- Analyst Target Upside↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Mar 25, 2026
Immix Biopharma, Inc. (IMMX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $8.13: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 15%; Below-average business quality; Negative price momentum.
Immix Biopharma is a clinical-stage biopharmaceutical company developing CAR-T cell therapies, led by NXC-201, a next-generation BCMA-targeted CAR-T candidate for relapsed/refractory AL Amyloidosis currently in the Phase 1b/2 NEXICART-2 trial. NXC-201 holds FDA Breakthrough... Read more
Sell if holding. Engine safety override at $8.13: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 15%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.9/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About Immix Biopharma, Inc.
About Immix Biopharma, Inc.
Immix Biopharma's lead program, NXC-201, is a next-generation CAR-T candidate targeting BCMA under evaluation in the U.S. Phase 1b/2 NEXICART-2 trial and the ex-U.S. Phase 1b/2a NEXICART-1 trial, reporting a 75% complete response rate in interim Phase 2 data presented at the American Society of Hematology's December 2025 annual meeting. NXC-201 has received FDA Breakthrough Therapy designation (January 2026), RMAT designation, and Orphan Drug Designation from both the FDA and European Commission for relapsed/refractory AL Amyloidosis, a disease with no FDA-approved therapies as of March 2026.
As a clinical-stage company, Immix Biopharma generates no product revenue and instead funds NXC-201's development through equity financings, including a $100.0 million public offering in December 2025 led by Morgan Stanley and a $9.3 million private placement in September 2025, along with an $8 million grant from the California Institute for Regenerative Medicine, of which $6.2 million had been received as of March 2026. The company relies on third-party contract manufacturers to produce NXC-201's active pharmaceutical ingredients and drug product for both clinical testing and, if approved, commercial supply, having deliberately avoided building its own manufacturing infrastructure. NEXICART-2 is expected to enroll 40 patients across 18 sites led by Memorial Sloan Kettering Cancer Center, with a final data readout and planned Biologics License Application submission to follow. Disclosed competitors pursuing AL amyloidosis therapies include AbbVie, Alexion/AstraZeneca (via Caelum Biosciences), and Janssen/Johnson & Johnson.
Show full overview
Immix Biopharma's entire clinical and financial thesis rests on NXC-201: the company has no products approved for sale in any country and has generated no revenue from product sales or licensing to date, reporting a $29.4 million net loss for 2025 against $100.4 million of cash, cash equivalents, and short-term investments as of December 31, 2025. Because NEXICART-2's registrational design is built around a single-arm, open-label trial enrolling just 40 patients, any negative or inconclusive final readout, or an FDA determination that the trial design does not support a Biologics License Application, would leave the company without a near-term path to its first approved product or first dollar of product revenue.
See also: Healthcare · Biotechnology
From Immix Biopharma, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Immix Biopharma, Inc.
Latest news
- NEWS Immatics Announced At ESMO Saturday, Updated Phase 1b IMA402 Data Showing 32% Confirmed Response Rate, 12.5-Month Media — benzinga Oct 25, 2026 positive
- NEWS Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30 — benzinga Sep 29, 2026 positive
- NEWS Immix Biopharma Announces Pricing Of $125M Offering Of 11,363,637 Shares At $11.00/Share — benzinga Sep 29, 2026 positive
- NEWS Immix Biopharma Reports 89% Complete Response Rate In Interim Phase 2 Data For NXC-201 In AL Amyloidosis; Plans BLA Subm — benzinga Sep 29, 2026 positive
- NEWS Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19 — benzinga Aug 11, 2026 neutral
Generated 2026-10-29T11:48:40Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineNXC-20110-K Item 1: 'Our lead cell therapy candidate is CAR-T NXC-201 ("NXC-201"), currently being evaluated in our ongoing United States Phase 1b/2 NEXICART-2 (NCT06097832) clinical trial and an ex-U.S. phase 1b/2a NEXICART-1 (NCT04720313) clinical trial.'
- HIGHSupplierthird-party CMOs10-K Item 1: 'We rely, and expect to continue to rely for the foreseeable future on third-party CMOs to produce our product candidates for pre-clinical and clinical testing, as well as for commercial manufacture if our product candidates receive marketing approval.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.13: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 15%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $7.61. Score 4.9/10, moderate confidence.
Resistance target: $10.26 (+26.3% upside). Prior stop was $7.61. Stop-loss: $7.61.
Concentration risk — Pipeline: NXC-201; Concentration risk — Supplier: third-party CMOs; DATA_ISSUE: analyst_target_implausible (raw $24.43 vs price $8.12 — ratio 3.0×). Rejected, falling back to technical TP..
Immix Biopharma, Inc. trades at a P/E of N/A (forward -8.6). TrendMatrix value score: 5.0/10. Verdict: Sell.
13 analysts cover IMMX with a consensus score of 4.2/5. Average price target: $24.
What does Immix Biopharma, Inc. do?Immix Biopharma is a clinical-stage biopharmaceutical company developing CAR-T cell therapies, led by NXC-201, a...
Immix Biopharma is a clinical-stage biopharmaceutical company developing CAR-T cell therapies, led by NXC-201, a next-generation BCMA-targeted CAR-T candidate for relapsed/refractory AL Amyloidosis currently in the Phase 1b/2 NEXICART-2 trial. NXC-201 holds FDA Breakthrough Therapy, RMAT, and Orphan Drug designations and reported a 75% complete response rate in interim Phase 2 data presented at ASH 2025, but the company has no products approved or revenues from product sales, having reported a $29.4 million net loss and $104.5 million accumulated deficit for 2025.